Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 1,126 GBp
Change Today -2.00 / -0.18%
Volume 1.6M
SN/ On Other Exchanges
New York
As of 11:35 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

smith & nephew plc (SN/) Snapshot

1,137 GBp
Previous Close
1,128 GBp
Day High
1,137 GBp
Day Low
1,124 GBp
52 Week High
03/3/15 - 1,216 GBp
52 Week Low
10/16/14 - 881.00 GBp
Market Cap
Average Volume 10 Days
0.62 GBp
Shares Outstanding
0.34 GBp
Dividend Yield
Current Stock Chart for SMITH & NEPHEW PLC (SN/)

Related News

No related news articles were found.

smith & nephew plc (SN/) Related Businessweek News

No Related Businessweek News Found

smith & nephew plc (SN/) Details

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The company’s Advanced Surgical Devices segment offers orthopedic reconstruction products, including hip and knee implants, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints. In addition, this segment offers arthroscopy enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue; and gynecological instrumentation devices. The company’s Advanced Wound Management segment offers a range of products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns, and post-operative wounds. This segment also provides traditional and single-use negative pressure wound therapy and hydrosurgery systems; and biologics and other bioactive technology products for debridement and dermal repair/regeneration. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

14,000 Employees
Last Reported Date: 07/30/15
Founded in 1856

smith & nephew plc (SN/) Top Compensated Officers

Chief Executive Officer, Director, Chairman o...
Total Annual Compensation: $3.2M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: $1.8M
Compensation as of Fiscal Year 2014.

smith & nephew plc (SN/) Key Developments

Colombian Surgeon Performs First Total Knee Replacement Using Smith & Nephew's VISIONAIRE™ Cutting Guides in Latin America

Smith & Nephew announced the successful outcome of the first total knee replacement in Colombia using the innovative VISIONAIRE Cutting Guides. The surgery, which was performed by Dr. César Rocha at Fundación Cardio Infantil de Bogotá, demonstrates the expanding global popularity of the pioneering, patient-specific VISIONAIRE instrumentation, as well as the company's increasing presence in the Latin American joint replacement market. VISIONAIRE Cutting Guides are single-use, surgical instruments designed using MRI and X-Ray data to accurately match the unique anatomy of each patient's knee joint. The precise fit of the cutting guides allows a surgeon to accommodate the specific shapes and angles of the joint while aligning the implant to offer the desired outcome.

Smith & Nephew Launches TRIGEN META-TAN System

Smith & Nephew announced the launch of its TRIGEN META-TAN (Trochanteric Antegrade Nail) System at the Orthopaedic Trauma Association's (OTA) annual meeting in San Diego. The META-TAN System expands the clinically proven TRIGEN Nail portfolio with a versatile design that addresses a wide range of femoral fractures ranging from specific hip fractures to mid-shaft fractures and fractures near the knee. For hip fractures in patients with good bone quality, the META-TAN System features the company's unique dual integrated screw design which is able to gain and maintain compression of the proximal femur. Additionally, the thinner size of the new nail may also benefit patients with narrow femoral canals. For mid-shaft fractures and fractures near the knee, the variable bow of the nail provides versatile options for varying patient anatomy, and the multi-planar screw configuration allows for optimum fracture stability.

Smith & Nephew Launches New NASASTENT Dissolvable Nasal Dressing

Smith & Nephew announced the launch of its new NASASTENT Dissolvable Nasal Dressing, a structural intranasal splint used to minimize bleeding and prevent post-op adhesions after sinus surgery. Made from a plant-based material known as CarboxyMethyl Cellulose (CMC), the NASASTENT dressing can be easily customized by simply trimming it to fit the size needs of each patient and offers tapered edges for ease of placement into the nasal cavity. Once in place, the soft dressing quickly regains its shape as it conforms to the patient's anatomy; providing sufficient pressure to minimize bleeding and hold the surrounding soft tissues in place as they heal. Recent testing shows that the NASASTENT dressing's compressive strength is six-times greater than its competitor and provides significantly higher tissue separation force over a variety of simulated nasal cavity gaps ranging from 7 to 10mm. Also, unlike other structural dressings which break down into fragments that must be later removed by a physician, the CMC used in the NASASTENT dressing converts into a hydrocolloidal gel after absorbing sufficient nasal fluid and simply drains from the cavity as part of the natural outflow. CMC has a well-documented clinical history with over two decades of use in the pharmaceutical and medical device industries. The NASASTENT dressing is capable of absorbing up to 16-times its dry weight in fluid and does not require any special storage conditions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SN/:LN 1,126.00 GBp -2.00

SN/ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $186.71 USD -0.31
Edwards Lifesciences Corp $148.22 USD +1.95
St Jude Medical Inc $63.99 USD +0.80
Terumo Corp ¥3,355 JPY +35.00
Zimmer Biomet Holdings Inc $96.45 USD +1.01
View Industry Companies

Industry Analysis


Industry Average

Valuation SN/ Industry Range
Price/Earnings 28.0x
Price/Sales 3.3x
Price/Book 3.8x
Price/Cash Flow 27.8x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SMITH & NEPHEW PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at